Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.

Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, Chayvialle JA, Lombard-Bohas C.

Clin Colorectal Cancer. 2010 Oct;9(4):248-54. doi: 10.3816/CCC.2010.n.037.

PMID:
20920998
2.

5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.

Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L.

Cancer. 1998 Jul 15;83(2):372-8.

PMID:
9669822
3.

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E.

Ann Oncol. 2002 Apr;13(4):614-21.

4.

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM.

Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83. Review.

PMID:
12153595
5.

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.

Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, Bedenne L, Cadiot G.

Dig Liver Dis. 2011 Nov;43(11):912-6. doi: 10.1016/j.dld.2011.07.001. Epub 2011 Aug 9.

PMID:
21831734
6.

A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.

Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P.

Ann Oncol. 1995 Jan;6(1):77-9.

PMID:
7710986
7.

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T.

JOP. 2013 Sep 10;14(5):498-501. doi: 10.6092/1590-8577/1589.

8.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA.

Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.

PMID:
23370660
9.

Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.

Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S.

Cancer Chemother Pharmacol. 2004 Apr;53(4):337-40. Epub 2003 Dec 24.

PMID:
14704829
10.

Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.

Zhang CX, Huang S, Xu N, Fang JW, Shen P, Bao YH, Mou BH, Shi MG, Zhong XL, Xiong PJ.

Anticancer Drugs. 2007 Jun;18(5):581-6.

PMID:
17414627
11.

FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.

Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, Chahine G.

Am J Clin Oncol. 2007 Feb;30(1):15-20.

PMID:
17278889
12.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.

J Clin Oncol. 2006 Jan 20;24(3):401-6.

13.

Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.

Abbasi S, Kashashna A, Albaba H.

Pancreas. 2014 Nov;43(8):1303-5. doi: 10.1097/MPA.0000000000000174.

PMID:
25036906
14.

Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.

Zhu X, Leaw J, Gu W, Qian Y, Du H, Wang B, Hong X, Yin J.

J Cancer Res Clin Oncol. 2008 Sep;134(9):929-36. doi: 10.1007/s00432-008-0376-4. Epub 2008 Mar 15.

PMID:
18343948
15.

5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients.

Ozkan K, Turkkan E, Ender K, Mutlu D, Murat A, Nalan B, Abdulmecit Y, Osman M.

Indian J Cancer. 2005 Apr-Jun;42(2):85-8.

16.

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.

Ducreux MP, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, Elias D, de Baere T, Sabourin JC, Duvillard P, Lasser P, Schlumberger M, Baudin E.

Oncology. 2006;70(2):134-40. Epub 2006 Apr 26.

PMID:
16645326
18.

Chemotherapy in the treatment of neuroendocrine malignant tumors.

Rougier P, Mitry E.

Digestion. 2000;62 Suppl 1:73-8. Review.

PMID:
10940691
19.

Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.

Raderer M, Kornek GV, Hejna MH, Weinlaender G, Vorbeck F, Fiebiger WC, Scheithauer W.

Ann Oncol. 1997 Aug;8(8):797-9.

Items per page

Supplemental Content

Write to the Help Desk